Pregabalin in neuropsychiatry Review article

Article Sidebar

PDF (Język Polski)


Published: Sep 30, 2016
Keywords:
pregabalin, generalized anxiety disorder

Main Article Content

Bartosz Łoza
Klinika Psychiatrii Oddziału Fizjoterapii Warszawskiego Uniwersytetu Medycznego
Maja Polikowska
Klinika Psychiatrii Oddziału Fizjoterapii Warszawskiego Uniwersytetu Medycznego
Adam Bycul
Klinika Psychiatrii Oddziału Fizjoterapii Warszawskiego Uniwersytetu Medycznego
Mariusz Bartyzel
Klinika Psychiatrii Oddziału Fizjoterapii Warszawskiego Uniwersytetu Medycznego

Abstract

Pregabalin is a medication used to treat generalized anxiety disorder (GAD), fibromyalgia, epilepsy (as an add-on therapy for partial seizures), and neuropathic pain syndromes. Some off-label uses of pregabalin include social anxiety disorder, alcohol or benzodiazepine withdrawal, restless leg syndrome, and migraines. It may decrease the use of opioids in various pain syndromes. Pregabalin can be considered as an alternative to benzodiazepines and antidepressants for anxiolytic treatment. It has become a major treatment for treatment-refractory anxiety in Europe.

Article Details

Issue
Vol 8 No 3 (2016)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Hoppa MB, Lana B, Margas W et al. α2δ expression sets presynaptic calcium channel abundance and release probability. Nature 2012. http://doi.org/10.1038/nature11033.
2. Aupperle RL, Tankersley D, Ravindran LN et al. Pregabalin effects on neural response to emotional faces. Front Hum Neurosci 2012; 6: 42.
3. EMA .
4. FDA .
5. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 2014; 28(9): 835-854.
6. Álvarez E, Olivares JM, Carrasco JL et al. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors. Ann Gen Psychiatry 2015; 14(1): 2.
7. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18(6): 422-430.
8. Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010; 11(3): 456-465.
9. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 2007; 64(14): 1475-1482.
10. Bockbrader HN, Wesche D, Miller R et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinetics 2010; 49(10): 661-669.
11. Kontoangelos KA, Kouzoupis AV, Ferentinos PP et al. Pregabalin for opioid-refractory pain in a patient with ankylosing spondylitis. Case Rep Psychiatry 2013; 2013: 912409. http://doi.org/10.1155/2013/912409.
12. Bhusal S, Diomampo S, Magrey MN. Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug Health Patient Saf 2016; 8: 13-23.
13. Beydoun A, Uthman BM, Kugler AR et al; Pregabalin 1008-009 Study Group. Safety and Efficacy of Two Pregabalin Regimens for Add-on Treatment of Partial Epilepsy. Neurology 2005; 64: 475-480.
14. Kwon OY, Park SP. Depression and anxiety in people with epilepsy. J Clin Neurol 2014; 10(3): 175-188.
15. Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging Drugs for the Treatment of Anxiety. Expert Opin Emerg Drugs 2015; 20(3): 393-406.
16. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26(4): 213-220.
17. Griffin E, Brown JN. Pregabalin for the Treatment of Restless Legs Syndrome. Ann Pharmacother 2016; 50(7): 586-591.
18. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs 2012; 21(7): 1019-1029.
19. Kämmerer N, Lemenager T, Grosshans M et al. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax 2012; 39(7): 351-352.
20. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F et al. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol 2010; 33(1): 35-39.
21. Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;(6): CD010609. http://doi.org/10.1002/14651858.CD010609.
22. Marks DM, Patkar AA, Masand PS, Pae CU. Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective. Psychiatry Investig 2009; 6(2): 55-58.